Hypertrophic obstructive cardiomyopathy as a side effect of dexamethasone treatment for bronchopulmonary dysplasia
- 1 June 1993
- journal article
- case report
- Published by Wiley in Acta Paediatrica
- Vol. 82 (6-7) , 614-617
- https://doi.org/10.1111/j.1651-2227.1993.tb12771.x
Abstract
We report three infants who developed hypertrophic obstructive cardiomyopathy during dexamethasone treatment for bronchopulmonary dysplasia. In all three infants, echocardiography had ruled out cardiac abnormalities prior to the dexamethasone course. The hypertrophic obstructive cardiomyopathy appeared and progressed during dexamethasone therapy and resolved completely after its cessation. This suggests a causative association between the hypertrophic obstructive cardiomyopathy and the exogenous glucocorticosteroid therapy. The mechanism of this dexamethasone-related hypertrophic obstructive cardiomyopathy is unclear. This complication may be encountered more frequently with the increasing use of dexamethasone in infants with bronchopulmonary dysplasia.Keywords
This publication has 16 references indexed in Scilit:
- Hypertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysplasiaThe Journal of Pediatrics, 1992
- Dexamethasone and hypertension in preterm infantsEuropean Journal of Pediatrics, 1992
- Dexamethasone treatment during ventilator dependency: possible life threatening gastrointestinal complications.Archives of Disease in Childhood, 1992
- Catabolic effect of dexamethasone in the preterm baby.Archives of Disease in Childhood, 1992
- Dexamethasone therapy for chronic lung disease in ventilator- and oxygen-dependent infants: A controlled trialThe Journal of Pediatrics, 1989
- A Controlled Trial of Dexamethasone in Preterm Infants at High Risk for Bronchopulmonary DysplasiaNew England Journal of Medicine, 1989
- Cardiac hypertrophy secondary to ACTH treatment in childrenEuropean Journal of Pediatrics, 1984
- Steroid-induced hypertrophic cardiomyopathy in an infantPediatric Cardiology, 1984
- Anti-inflammatory steroids reduce tissue PG synthetase activity and enhance PG breakdownNature, 1980